ストックスクリーナーアプリを入手
16.02
2.02%
-0.33
アフターアワーズ：
16.06
0.04
+0.25%
Avalo Therapeutics Inc (AVTX) 最新ニュース
Point72 (AVTX) reports 2.71M-share, 5.2% position in Avalo Therapeutics - Stock Titan
Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028 - Stock Titan
Avalo Therapeutics (AVTX) CFO receives 39,900 PSU-linked shares in equity award - Stock Titan
Avalo Therapeutics (AVTX) CLO granted 24,300 performance-based common shares - Stock Titan
Avalo Therapeutics (AVTX) CMO receives 43,500-share performance award - Stock Titan
Performance stock units expand Avalo (NASDAQ: AVTX) CEO’s stake - Stock Titan
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan - Stock Titan
Avalo Therapeutics (AVTX) price target increased by 18.49% to 47.94 - MSN
UBS Group AG Has $8.68 Million Stock Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty - TipRanks
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
Logos Global (AVTX) discloses 1.675M-share position, 3.2% of stock - Stock Titan
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
RA Capital and principals report 9.99% stake in Avalo Therapeutics (AVTX) - Stock Titan
OrbiMed reports 475,165 Avalo Therapeutics shares (AVTX) at 2.1% - Stock Titan
BVF affiliates report ~2.35M AVTX shares (NYSE: AVTX) under group attribution - Stock Titan
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $55 - Moomoo
Caligan Partners and David Johnson report 7.2% stake in Avalo (AVTX) - Stock Titan
T. Rowe Price (AVTX) shows 2.16M shares, 9.5% of Avalo Therapeutics - Stock Titan
Avoro holds 1.41M shares in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results - Sahm
Apple To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Avalo Therapeutics stock jumps 33% in pre-market session: Here's why - MSN
Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $34 - Moomoo
AVTX Maintains by Citizens -- Price Target Lowered to $55.00 - GuruFocus
AVTX Maintained by Mizuho -- Price Target Raised to $45.00 - GuruFocus
Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
AVTX Maintained by Wedbush -- Price Target Lowered to $34.00 - GuruFocus
AVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating - Moomoo
Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00 - MarketBeat
Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating - Moomoo
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58 - Moomoo
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data - Investing.com UK
Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $35.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data By Investing.com - Investing.com South Africa
Citizens cuts Avalo Therapeutics stock price target on equity financing - Investing.com UK
Citizens cuts Avalo Therapeutics stock price target on equity financing By Investing.com - Investing.com Australia
AVTX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.27, Implies 137% Upside - TradingView
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside - TradingView
Avalon (AVTX) Reports Promising Trial Results for Abdakibart in HS Treatment - GuruFocus
Avalo Therapeutics Q1 Net Loss Narrows - Moomoo
Avalo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and SEC Filings Overview - Minichart
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $48.7, Implies 144% Upside - TradingView
Avalo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Avalo Therapeutics Reports Positive Phase 2 Results for Abdakibart in Hidradenitis Suppurativa and Raises $431M to Fund Phase 3 Trial - Minichart
Is Avalo Therapeutics (AVTX) Overvalued After Q1 2026 EPS Beat? - GuruFocus
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):